Cardio-oncology
Overview
Cardio-oncology is a scientific journal, published by Biomed Central since 2015 in English. The journal's country of origin is United Kingdom and its primary focus area is oncology.
Details
Details
Abbr.
Cardiooncology
Publisher
Biomed Central
Start
2015
End
Continuing
e-ISSN
2057-3804
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 12197
21
SJR / Ranks: 4081
958
CiteScore / Ranks: 4502
5.40
Recent Articles
1.
Cirne F, Sedelaar M, Narayan V, Macedo A, Koo C, de Jesus J, et al.
Cardiooncology
. 2025 Mar;
11(1):28.
PMID: 40089789
Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of non-cancer comorbidities,...
2.
Boen H, Pype L, Papadimitriou K, Altintas S, Teuwen L, Anguille S, et al.
Cardiooncology
. 2025 Mar;
11(1):27.
PMID: 40087712
Background: SERPINA3 recently emerged as potential prognostic biomarker in heart failure. In a population of cancer survivors with cancer therapy-related cardiac dysfunction (CTRCD) circulating SERPINA3 was elevated compared to age-matched...
3.
Ozaki A, Sayer M, Hamano H, Nagasaka M, Lee B, Doh J, et al.
Cardiooncology
. 2025 Mar;
11(1):26.
PMID: 40045435
Introduction: Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights. Methods: We performed...
4.
5.
Wilson O, Wojcik K, Cohen C, Kamil D, Butera G, Matthews C, et al.
Cardiooncology
. 2025 Feb;
11(1):24.
PMID: 40012001
Background: Breast cancer survivors are at increased risk of cardiovascular events due to the cardiotoxic effects of cancer treatment. Exercise participation can lower the risk of various adverse cardiovascular health...
6.
Forbes Z, Dunmall T, Tey A, Culligan D, Fedele P
Cardiooncology
. 2025 Feb;
11(1):22.
PMID: 40001259
Background: Anthracycline induced cardiomyopathy (AIC) is an important complication of cancer management. Recent findings showed that with early identification and intervention, AIC may be fully or partially reversible. European society...
7.
Sharma A, Fierro M, Governor S, Kothare A, Pak S, Liu K, et al.
Cardiooncology
. 2025 Feb;
11(1):23.
PMID: 40001253
Background: Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), is often the first line treatment for HER2 positive breast cancer. Although trastuzumab is effective, it has...
8.
Sabate-Tormos M, Bardaji A, Peiro O, Carrasquer A, Cediel G, Ferreiro J
Cardiooncology
. 2025 Feb;
11(1):21.
PMID: 39987454
Background: Cancer and cardiovascular diseases are the leading causes of mortality worldwide, as they share common risk factors and exacerbate cardiovascular outcomes when they coexist. This study aimed to assess...
9.
Zeng J, Yu J, Mei Q, Yuan Y, Zhang T, Mei L, et al.
Cardiooncology
. 2025 Feb;
11(1):20.
PMID: 39985092
Background: For patients diagnosed with both lung cancer and severe coronary heart disease (CHD), the conflict between revascularization and lung cancer surgery remains to be settled to balance how to...
10.